New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
05:36 EDTBAYRY, REGNRegeneron, Bayer submit Eylea Injection for EU marketing authorization
Regeneron Pharmaceuticals (REGN) and Bayer HealthCare (BAYRY) announced that Bayer HealthCare has submitted an application to the European Medicines Agency seeking marketing authorization in the European Union for Eylea Injection for the treatment of macular edema following branch retinal vein occlusion, or BRVO. The EMA submission is based on the positive Phase 3 VIBRANT trial, a double-masked, randomized, active-controlled study of patients with macular edema following BRVO. In the VIBRANT study, 53% of patients who received EYLEA 2 milligram monthly gained at least 15 letters in best-corrected visual acuity, or BCVA, from baseline at week 24, the primary endpoint of the study, compared to 27 of patients who received laser, a standard of care treatment. In addition, EYLEA met a key secondary endpoint, achieving a 17.0 letter mean improvement over baseline in BCVA compared to a 6.9 letter mean improvement in patients who received laser.
News For REGN;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
05:23 EDTREGNSanofi, Regeneron announce Praluent ODYSSEY OUTCOMES trial enrollment complete
Subscribe for More Information
November 18, 2015
06:03 EDTBAYRYBayer says not looking to sell crop chemicals business, Reuters reports
Bayer (BAYRY) says its Bayer CropScience unit is an "integral part" of the company and that the division is not for sale, Reuters reports. Bayer's comments come after Monsanto (MON) executives said that it is in internal discussions about tie-ups in the industry. Reference Link
November 15, 2015
13:04 EDTBAYRYBayer shares could advance 25% in a year, Barron's says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use